🚀 Zacks Small Cap Research - PLX: Elfabrio Estimates Up, Again
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-plx-elfabrio-estimates-up-again/
#PLX #Prot#PLXB#ProtalixBioTherapeutics #Elfabrio##ElelysoA#PRX115##ACR2026##Biotecht#BiotechStocks #SmallCape#E/hashtag/StockResearch" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#StockResearch

Treatment, part one: enzyme replacement therapy, manufactured in a lab and given by IV about every 2 weeks. Imiglucerase (Cerezyme, 1994), velaglucerase alfa (VPRIV, 2010), and taliglucerase alfa (Elelyso, 2012), the last of which is grown in genetically engineered carrot cells.

Protalix CEO Dror Bashan pens letter to stockholders emphasizing:
*Development
~Ph2 PRX115
~Renal pipeline-PRX119
~Secarna OligoCreator
*Chiesi, Elfabrio & CHMP flexible dosing
*Dec'25 BioMarin/Amicus Galafold acq
*Elelyso
$PLX
ir.protalix.com/news-release...

Protalix reports 1Q25
*Call @ 8:30 am ET
*Revs of $10.1mm, up on higher Elelyso sales
*EPS ($0.05)
$PLX
finance.yahoo.com/news/protali...

We've covered Protalix Biotherapeutics for several years & $PLX's fortunes have radically changed for the better. See our video introduction as to why the sponsor of Elfabrio & Elelyso has a bright future.
www.youtube.com/watch?v=CZcr...

Protalix_Bio CEO Dror Bashan pens shareholder letter & addresses:
*EMA dosing submission
*PRX115
*PRX119
*ProCellEx & renal rare disease
*Elfabrio & Elelyso
*Debt repaid
$PLX
finance.yahoo.com/news/protali...

The answer is A, taliglucerase alfa (Elelyso). The biosynthetic form of human beta-glucocerebrosidase is indicated for long term enzyme replacement in patients with nonneuronopathic (type 1) Gaucher disease. It is an orphan drug.

Gen İlaç, Pfizer PFE İlaçları A.Ş. ile Elelyso ve Besponsa ürünlerinin Türkiye’de 5 yıl süreyle satış, pazarlama ve dağıtımı için anlaşma yaptı.

#GENIL #genil